Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
Brief Summary: The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.


Options:
A: Arm Label: Part 1: Single Dose Escalation in Healthy Subjects; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805 10mg, Drug: GSK2336805 30mg, Drug: GSK2236805 100mg, Drug: GSK2236805 200mg | Arm Label: Part 2: Repeat Dose Escalation in Healthy Subjects; Type: EXPERIMENTAL; Interventions: Drug: GSK2236805 10mg, Drug: GSK2236805 dose to be determined up to 100mg | Arm Label: Part 3: Single Dose Escalation in HCV Infected Subjects; Type: EXPERIMENTAL; Interventions: Drug: GSK2236805 5mg, Drug: GSK2236805 30mg, Drug: GSK2236805 100mg | Intervention Type: DRUG; Name: GSK2336805 10mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2336805 30mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 100mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 200mg; Assigned to Arm(s): Part 1: Single Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 10mg; Assigned to Arm(s): Part 2: Repeat Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 dose to be determined up to 100mg; Assigned to Arm(s): Part 2: Repeat Dose Escalation in Healthy Subjects | Intervention Type: DRUG; Name: GSK2236805 5mg; Assigned to Arm(s): Part 3: Single Dose Escalation in HCV Infected Subjects | Intervention Type: DRUG; Name: GSK2236805 30mg; Assigned to Arm(s): Part 3: Single Dose Escalation in HCV Infected Subjects | Intervention Type: DRUG; Name: GSK2236805 100mg; Assigned to Arm(s): Part 3: Single Dose Escalation in HCV Infected Subjects
B: Arm Label: Arm 1: Null or Partial Responder to P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 3: Treatment naive (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Arm Label: Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week; Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Asunaprevir (ASV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Daclatasvir (DCV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Pegylated-interferon alfa 2a (PegIFN); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C
D: Arm Label: Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (B); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (C); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Placebo, Peginterferon alpha-2a, ribavirin (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (C) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: Peginterferon alpha-2a; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D)

Answer: D